Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Abstract

The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.

1 - 17 . (canceled) 
   
   
       18 . A pharmaceutical combination comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof and candesartan. 
   
   
       19 - 21 . (canceled) 
   
   
       22 . A pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof, candesartan and a pharmaceutically acceptable diluent or carrier. 
   
   
       23 . A unit dosage formulation comprising a pharmaceutical combination according to  claim 18 . 
   
   
       24 . A unit dosage formulation comprising a pharmaceutical composition according to  claim 22 . 
   
   
       25 . The unit dosage formulation of  claim 18  or  claim 22  wherein the (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5 S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof is present in said formulation in an amount of from 5 to 80 mg, and the candesartan is present in an amount of from 0.1 to 100 mg.